Compare Repligen Corporation Common Stock (RGEN) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs ProShares UltraPro S&P500 — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while ProShares UltraPro S&P500 trades at $148.71 (market cap $5.68B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and ProShares UltraPro S&P500 is more actively traded (2,478,701 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and ProShares UltraPro S&P500 for 30 Days on average.
| RGEN | UPRO | |
|---|---|---|
Market Cap | $11.31B | $5.68B |
Volume | 1,216,919 | 2,478,701 |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.57 | $157.66 |
52-Week Low | $102.87 | $89.29 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $11.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
UPRO trades at $155.38, showing minimal daily movement with a slight 0.05% decline. The technical outlook remains bullish with strong moving average signals, though oscillators indicate neutral momentum. Recent news highlights S&P 500 valuation concerns and expected profit growth deceleration from 35% in 2026 to 15% in 2027, creating mixed sentiment for this leveraged ETF.
As a leveraged S&P 500 ETF, UPRO's performance is tied to broader market movements. Current technical strength supports near-term upside potential, but elevated RSI levels and slowing earnings growth projections for the underlying index present headwinds. The ETF's leveraged structure amplifies both gains and losses, requiring careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
